Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases


DEVECİ M. A. , PAYDAŞ S. , GÖNLÜŞEN G. , ÖZKAN C. , BİÇER Ö. S. , TEKİN M.

ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, cilt.51, ss.1-6, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 51 Konu: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.aott.2016.03.004
  • Dergi Adı: ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA
  • Sayfa Sayısı: ss.1-6

Özet

Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assess adverse effect profile and recurrence rate.